ClinicalTrials.gg
Active, not recruitingNCT06406855Updated Oct 2, 2026

Brain-Controlled Spinal Stimulation Walking Therapy After Incomplete Spinal Cord Injury (SCI)

An interventional study of Brain-Computer Interface-Triggered Transcutaneous Spinal Cord Stimulation (BCI-tSCS) System in Spinal Cord Injuries, sponsored by University of Miami. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of Miami · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 45 studies in Spinal Cord Injuries by University of Miami — 12 open to participants now, 14 under way, 1 of them phase 3. Spinal Cord Injuries · University of Miami.

Enrollment
31st of 37
6 · median 26
Started
2024
with 5 others
No phase
33 of 45
10 open now
Primary completion
2026-12
later than 0 of 13 live
Registered
37th of 45
by date

Among the 45 studies in Spinal Cord Injuries by University of Miami, this one is the 31st largest by enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2024, is one of 33 with no phase, reaches primary completion later than 0 of the 13 other live ones, and was the 37th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

12 of the 45 studies in Spinal Cord Injuries by University of Miami are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Spinal Cord Injuries by University of Miami, or all of them as a file.
02

Study summary

The purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).

03

Conditions studied

  • Spinal Cord Injuries
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old and no older than 70 years old at the time of enrollment.
  2. Traumatic incomplete spinal cord injury (neurological level at or above T10 spinal cord level; Abbreviated Injury Scale (AIS) C or D impairment grade for group 1, 3 and 4 and AIS B, C or D impairment grade for group 2), who are more than 6 months post-injury.
  3. Has detectable motor function in at least 2 muscles per side confirmed by voluntary Electromyography (EMG) or detectable tibialis anterior (TA) muscle motor evoked potentials (MEPs) at the baseline assessment.
  4. Able to commit to intensive training and assessment sessions over a maximum total duration of 12 months (6 months of treatment).
  5. Could effectively walk overground for at least 10 meters with some assistance of a therapist and minimal body-weight support, with functional spasticity (by participant's self-report), functional range-of-motion of lower limb joints, and acceptable bone mass to enable body-weight support, confirmed by Dual-energy X-ray absorptiometry (DXA) scan.

Exclusion criteria

Exclusion Criteria:

  1. Has traumatic brain injury, stroke, multiple sclerosis, or other neuromuscular disorders that could affect neuromotor function and walking.
  2. Has severe spasticity that could prevent stepping and walking function determined by the investigator.
  3. Has major executive dysfunction, dementia, depression, neurocognitive impairments, or other major medical co-morbidities.
  4. Has other for transcranial magnetic stimulation (TMS) or Transcutaneous Spinal Cord Stimulation (TSCS).
  5. Has a history of recent seizures or poorly managed autonomic dysreflexia that could be triggered by TMS or TSCS.
  6. Has a history of prior intracranial surgery or known lesions that would limit TMS assessments and Brain-Computer Interface (BCI) recordings.
  7. Individuals with metal implants in their head and other implantable devices in the body that could be affected by TMS or TSCS.
  8. Has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.).
  9. Has urinary tract infection, unhealed fracture, contracture, and pressure sore (Braden Scale).
  10. Has breakdown in skin area that will come into contact with electrodes.
  11. Individuals who require therapy or other care that could interfere with participation in the study.
  12. Individuals on drugs or any other intervention known to have a potential impact on neuromotor function.
  13. Individuals with substance disorders, including alcoholism and drug abuse.
  14. Individuals who are pregnant, breastfeeding, or the desire to become pregnant during the study.
  15. In the opinion of the investigators, the study is not safe or appropriate for the participant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS)

    Participants will receive brain-computer interface (BCI)-triggered transcutaneous spinal cord stimulation (tSCS) combined with activity-based training 3 to 4 times per week. The BCI system detects movement attempts and triggers stimulation delivered through the Neostim 5 spinal cord stimulator. Participants will participate in the therapy for up to 12 months.

    Device: Brain-Computer Interface-Triggered Transcutaneous Spinal Cord Stimulation (BCI-tSCS) System

Interventions

  • DeviceBrain-Computer Interface-Triggered Transcutaneous Spinal Cord Stimulation (BCI-tSCS) System

    Participants will receive brain-computer interface (BCI)-triggered transcutaneous spinal cord stimulation (tSCS) using the Neostim 5 spinal cord stimulator during activity-based training sessions. The BCI system detects movement attempts and triggers delivery of transcutaneous spinal cord stimulation. Intervention sessions will occur 3 to 4 times per week throughout the study intervention period.

    Also known as: Neostim 5 Spinal Cord Stimulator

06

What researchers measure

Primary outcomes

  1. Number of related neurological deterioration (LEMS)

    Lower Extremity Motor Score (LEMS) to assess lower limb muscle function following the American Spinal Injury Association Impairment Scale (ASIA) guidelines. The LEMS evaluates motor function on a scale of 0 (no motor function) to 5 (full motor function).

    Time frame: up to 12 months

  2. Number of treatment related incidence of adverse events (AEs)

    Safety will be reported as the incidence of treatment related AEs as assessed by the study doctor

    Time frame: up to 12 months

  3. Number of subjects that complete the study

    Safety will be determined by number of subjects that complete the study, as designed.

    Time frame: up to 12 months

  4. Walking function using 10 meter walk test (10MWT)

    This is a test of short-distance walking function. The subject will be asked to walk at a comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway. Time is measured in meters per seconds.

    Time frame: up to 12 months

  5. Walking function using 6 minute walk test (6MWT)

    The object of the test is to walk as far as possible for 6 minutes. The subject will walk at a normal pace around a marked course for 6 minutes. The subject may stop to rest and begin again at will. The distance covered indicates aerobic fitness. The further a subject walks, the better their cardiovascular condition. Units are measured in meters.

    Time frame: up to 12 months

Secondary outcomes

  1. Mobility measured by Timed Up and Go (TUG) Test

    The Timed Up and Go test or TUG test is used to help evaluate mobility. It measures, in seconds, how long it takes subjects to stand up, walk 10 feet, turn around, walk back, and sit down.

    Time frame: up to 12 months.

  2. Balance measured by the Berg Balance Scale (BBS)

    BBS is an assessment to determine balance. The BBS consists of 14 items scored on a 5-point ordinal scale, ranging from 0 to 4 (0 indicates lowest level of function; 4 indicates highest level of function), with a maximum total score of 56.

    Time frame: up to 12 months.

  3. Muscular spasticity measured by the Modified Ashworth Scale (MAS)

    The Modified Ashworth Scale is a 6-point scale. Scores range from 0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity.

    Time frame: up to 12 months.

  4. Muscular spasticity measured by the Pendulum Test

    The Pendulum Test will be used to measure muscular spasticity. During the pendulum test, the participant will be lying on a therapy mat with the lower leg hanging off the edge of the mat. A member of the study staff will support the participant's extended lower leg and then release the leg allowing it to swing freely. This test will be video recorded and the movement of the knee joint will be measured using software on the computer. Muscular spasticity will be calculated by the number of the Relaxation index (R1 and R2) and compared to norms.

    Time frame: up to 12 months.

  5. Walking assistance measured by the Walking Index for Spinal Cord Injury Scale (WISCI II)

    WISCI II is an ordinal scale using a rank ordering along a dimension of impairment, from the level of most severe impairment (0) to least severe impairment (20) based on the use of devices, braces and physical assistance of one or more persons. The order of the levels suggests each successive level is a less impaired level than the former.

    Time frame: up to 12 months

  6. Independence as measured by Spinal Cord Independence Measure (SCIM III)

    SCIM III assesses performance in activities of daily living Scores range from 0-100, where a score of 0 defines total dependence and a score of 100 is indicative of complete independence.

    Time frame: up to 12 months

  7. Quality of Life using the International Spinal Cord Injury - Quality of Life (ISCI-QOL)

    ISCI-QOL consists of three single items on satisfaction with life as a whole, physical health and psychological health using a 0-10 scale where 0=complete dissatisfaction; 10=complete satisfaction.

    Time frame: up to 12 months

  8. Quality of Life measured by the Reintegration to Normal Living (RNL) questionnaires

    RNL is a self-report questionnaire that assesses a person's satisfaction with performance in life activities. The RNL index assesses mobility, self-care, daily activity, recreational activity, and family roles. The RNL includes 11 declarative statements and a composite score will be calculated. Minimum Score = 0; Maximum Score = 100. Higher scores indicate greater reintegration.

    Time frame: up to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 31 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartActual
May 7, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Enrollment
12 (estimated)→6 (actual)
Oct 2, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAble to commit to intensive training and assessment sessions over a maximum total duration of 12 months (6 months of treatment).
Oct 2, 2026
Interventions
Added Device: Brain-Computer Interface-Triggered Transcutaneous Spinal Cord Stimulation (BCI-tSCS) System; removed BCI-TSCS
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    Enrollment 12 (estimated)→6 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAble to commit to intensive training and assessment sessions over a maximum total duration of 12 months (6 months of treatment).
    Interventions Added Device: Brain-Computer Interface-Triggered Transcutaneous Spinal Cord Stimulation (BCI-tSCS) System; removed BCI-TSCS
    + 5 other changes: oversight details, design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06406855
Collaborators
United States Department of Defense
Responsible party
Matija Milosevic (Assistant Professor, University of Miami) — Principal investigator
First posted
May 9, 2024
Start date
May 7, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Matija Milosevic, PhD
principal investigator · University of Miami - MSOM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion